Account Executive

Telefónica and Harrison.ai join forces to support the diagnosis of chest X-rays using AI. - Telefónica is offering a solution in Spain based on artificial intelligence that is capable of analysing chest X-rays, automatically identifying up to 124 clinical findings and detecting other critical conditions at an early stage. - The solution will help healthcare professionals optimise their responses, streamline workflows and prioritise care for the most urgent cases. 21/07/2026 Reading time: 4 min Link copied. Telefónica, through its business unit Telefónica Tech, has partnered with the global healthcare technology company Harrison.ai to offer an artificial intelligence-based solution in Spain that will support healthcare professionals during the diagnostic process for chest X-rays. The technological solution incorporates a diagnostic support algorithm capable of analysing chest X-rays, automatically identifying up to 124 clinical findings (including pulmonary nodules to facilitate lung cancer screening) and detecting other critical conditions at an early stage. The artificial intelligence algorithm used has been trained using data from more than 780,000 chest X-ray studies, each of which has been independently labelled by at least three qualified radiologists to ensure diagnoses of a high standard of quality and reliability. Furthermore, the algorithm is certified as a medical device under the CE IIb marking, which provides the highest level of assurance in diagnostic support as it is authorised to address conditions that may pose a risk to patients' lives and guarantees compliance with the safety, efficacy and quality requirements set out in European Union legislation. The solution integrates into existing healthcare systems and infrastructure, thanks to the professional services provided by Telefónica's artificial intelligence and data experts, who ensure the technology can be adapted to the specific technical and clinical characteristics of each healthcare system. The company also provides managed maintenance and ongoing support services. Carlos Martínez, Head of Data and AI at Telefónica Tech, explains: "The incorporation of artificial intelligence into radiology represents a significant step towards more effective and efficient healthcare models, in which technology becomes an ally of healthcare professionals to deliver faster, more accurate and personalised care. With this new solution, which we are already offering to several regional health services, we are continuing to expand the services we offer our clients and making progress towards our aim of becoming the best gateway for citizens, businesses and public administrations to access digital technologies." "We are proud to partner with Telefónica Tech to bring clinically validated and scalable AI to healthcare professionals across Spain," says Dr Aengus Tran, CEO and co-founder of Harrison.ai. He adds: "Telefónica's reach in Spain gives us the opportunity to do what we set out to do: reduce the gap in healthcare capacity. Our aim is simple: to help clinicians detect diseases such as lung cancer at an earlier stage, prioritise the most urgent cases and ensure that no findings go unnoticed." This diagnostic support solution helps healthcare professionals improve patient care by optimising response times, streamlining workflows and enabling the early detection of diseases such as lung cancer. Artificial intelligence acts as a support tool, but it is the healthcare professional who retains the final say on the patient's assessment and the most appropriate course of treatment. A&E and primary care services will be able to view the diagnoses generated by artificial intelligence via a web-based viewer, which acts as an initial medical filter and helps to reduce unnecessary referrals to specialists. Furthermore, the solution integrates with the systems and patient lists that the radiologist needs to review, enabling them to customise the categorisation by level of urgency and prioritise the most urgent cases. Share it on your social networks Link copied. Word of the week

Jardine Matheson acquires I-MED Radiology Network in $2.4bn healthcare imaging deal. The acquisition combines diagnostic imaging scale with growing AI capabilities as healthcare investors target data-rich clinical infrastructure. Jardine Matheson has agreed to acquire Australian diagnostic imaging provider I-MED Radiology Network for an enterprise value of A$3.4bn ($2.4bn), securing one of the largest radiology and teleradiology platforms in the Asia-Pacific region. The deal includes I-MED's minority stake in Harrison.ai, an artificial intelligence company developing radiology tools for CT brain and chest imaging, adding an AI component to an already significant healthcare infrastructure acquisition. A strategic bet on diagnostic infrastructure. I-MED operates 215 clinics across Australia and New Zealand and performs more than seven million patient procedures annually through a network of over 500 radiologists. Its services span MRI, CT, PET, nuclear medicine, ultrasound, and X-ray imaging, providing coverage across both metropolitan and regional healthcare markets. Alongside its physical clinic footprint, I-MED has built a substantial teleradiology operation, delivering remote image interpretation services across Australia, New Zealand, and the United States. This combination of physical infrastructure, specialist workforce, and digital reporting capability makes I-MED one of the most comprehensive imaging platforms in the region. Why Harrison.ai matters. While the acquisition is primarily focused on I-MED's diagnostic imaging operations, the inclusion of its stake in Harrison.ai is strategically significant. Harrison.ai develops artificial intelligence solutions designed to support radiologists in interpreting medical imaging, including CT brain and chest scans. As imaging volumes continue to rise globally and radiologist shortages persist across multiple healthcare systems, AI-assisted diagnostics are increasingly viewed as a critical productivity and workflow enhancement tool. The transaction therefore provides Jardine Matheson with exposure not only to diagnostic imaging demand but also to one of healthcare's fastest-growing technology categories. Why this deal matters now. The acquisition reflects growing investor interest in healthcare infrastructure assets that sit at the intersection of service delivery, clinical data generation, and artificial intelligence. Diagnostic imaging occupies a particularly valuable position within healthcare because it combines: * Recurring patient demand * Large-scale clinical data generation * Increasing AI integration opportunities * Essential diagnostic workflows As healthcare systems seek to improve efficiency and address workforce shortages, imaging networks are becoming increasingly attractive strategic assets. The inclusion of Harrison.ai further reinforces the growing convergence between healthcare services and AI-enabled clinical decision support. What this means for the industry. The Jardine Matheson-I-MED transaction highlights several major trends shaping healthcare investment: * Diagnostic imaging is emerging as a high-value healthcare infrastructure asset class * AI is increasingly becoming embedded within clinical workflows rather than existing as a standalone technology category * Investors are targeting businesses that combine service delivery with proprietary healthcare data generation * Teleradiology continues to expand as healthcare systems seek greater workforce flexibility and coverage The deal also demonstrates how healthcare investors are increasingly seeking assets that provide both operational scale today and technology-driven growth opportunities tomorrow. Summary. Jardine Matheson's $2.4bn acquisition of I-MED Radiology Network represents a major investment in healthcare infrastructure, combining one of Australasia's largest diagnostic imaging providers with exposure to emerging AI-powered radiology technologies. As healthcare increasingly converges with data, diagnostics, and artificial intelligence, platforms capable of generating, interpreting, and scaling clinical insight are becoming some of the most strategically valuable assets in the sector. Discover how nuaxia can support your next medical education initiative: